212 related articles for article (PubMed ID: 36632151)
21. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer.
Cornford P; Bellmunt J; Bolla M; Briers E; De Santis M; Gross T; Henry AM; Joniau S; Lam TB; Mason MD; van der Poel HG; van der Kwast TH; Rouvière O; Wiegel T; Mottet N
Eur Urol; 2017 Apr; 71(4):630-642. PubMed ID: 27591931
[TBL] [Abstract][Full Text] [Related]
22. Lack of consensus identifies important areas for future clinical research: Advanced Prostate Cancer Consensus Conference (APCCC) 2019 findings.
Vogl UM; Beer TM; Davis ID; Shore ND; Sweeney CJ; Ost P; Attard G; Bossi A; de Bono J; Drake CG; Efstathiou E; Fanti S; Fizazi K; Halabi S; James N; Mottet N; Padhani AR; Roach M; Rubin M; Sartor O; Small E; Smith MR; Soule H; Sydes MR; Tombal B; Omlin A; Gillessen S;
Eur J Cancer; 2022 Jan; 160():24-60. PubMed ID: 34844839
[TBL] [Abstract][Full Text] [Related]
23. Evolving understanding and categorization of prostate cancer: preventing progression to metastatic castration-resistant prostate cancer: RADAR IV.
Crawford ED; Andriole G; Freedland SJ; Garnick M; Gomella LG; Henderson J; Higano CT; Kader AK; Kane C; Keane TE; Koo PJ; Petrylak DP; Reiter RE; Slovin SF; Yu EY
Can J Urol; 2020 Oct; 27(5):10352-10362. PubMed ID: 33049187
[TBL] [Abstract][Full Text] [Related]
24. Apalutamide, Darolutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC): A Critical Review.
Cattrini C; Caffo O; De Giorgi U; Mennitto A; Gennari A; Olmos D; Castro E
Cancers (Basel); 2022 Mar; 14(7):. PubMed ID: 35406564
[TBL] [Abstract][Full Text] [Related]
25. Current and potential future role of PSMA-PET in patients with castration-resistant prostate cancer.
Fankhauser CD; Poyet C; Kroeze SGC; Kranzbühler B; Schüler HIG; Guckenberger M; Kaufmann PA; Hermanns T; Burger IA
World J Urol; 2019 Mar; 37(3):457-467. PubMed ID: 30030659
[TBL] [Abstract][Full Text] [Related]
26. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer.
Aggarwal R; Wei X; Kim W; Small EJ; Ryan CJ; Carroll P; Cooperberg M; Evans MJ; Hope T
Eur Urol Oncol; 2018 May; 1(1):78-82. PubMed ID: 31100231
[TBL] [Abstract][Full Text] [Related]
27. [Interdisciplinary expert consensus on innovations in imaging diagnostics and radionuclide-based therapies for advanced prostate cancer].
Beyersdorff D; Rahbar K; Essler M; Ganswindt U; Grosu AL; Gschwend JE; Miller K; Scheidhauer K; Schlemmer HP; Wolff JM; Krause BJ
Urologe A; 2021 Dec; 60(12):1579-1585. PubMed ID: 34406465
[TBL] [Abstract][Full Text] [Related]
28. [Advanced Prostate Cancer Consensus Conference (APCCC) 2015 in St. Gallen : Critical review of the recommendations on diagnosis and therapy of metastatic prostate cancer by a German expert panel].
Thomas C; Bögemann M; König F; Machtens S; Schostak M; Steuber T; Heidenreich A
Urologe A; 2016 Jun; 55(6):772-82. PubMed ID: 26820660
[TBL] [Abstract][Full Text] [Related]
29. Assessment of real-world application of advanced prostate cancer management in Japan.
Aragon-Ching JB
Transl Androl Urol; 2022 Dec; 11(12):1614-1617. PubMed ID: 36632149
[No Abstract] [Full Text] [Related]
30. Abiraterone acetate versus nonsteroidal antiandrogen with androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
Yanagisawa T; Kimura T; Mori K; Suzuki H; Sano T; Otsuka T; Iwamoto Y; Fukuokaya W; Miyajima K; Enei Y; Sakanaka K; Matsukawa A; Onuma H; Obayashi K; Tsuzuki S; Hata K; Shimomura T; Miki J; Egawa S
Prostate; 2022 Jan; 82(1):3-12. PubMed ID: 34559410
[TBL] [Abstract][Full Text] [Related]
31. Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians.
Shore ND; Drake CG; Lin DW; Ryan CJ; Stratton KL; Dunshee C; Karsh LI; Kaul S; Kernen K; Pieczonka C; Sieber P; Stewart C; Williams M; Concepcion RS
Prostate; 2020 Oct; 80(14):1159-1176. PubMed ID: 32779781
[TBL] [Abstract][Full Text] [Related]
32. Management of patients with castration-resistant prostate cancer (CRPC): results of an Italian survey using the delphi method.
Terrone C; Berruti A; Papotti M; Vavassori V; Sciarra A
Tumori; 2016 Oct; 102(5):514-520. PubMed ID: 26166221
[TBL] [Abstract][Full Text] [Related]
33. Oligometastatic Lymph Node Recurrence Detected Using
Mori S; Kato T; Watabe T; Hatano K; Abe T; Fukuhara S; Kiuchi H; Imamura R; Uemura M; Nonomura N
Cancer Diagn Progn; 2022; 2(5):598-602. PubMed ID: 36060017
[TBL] [Abstract][Full Text] [Related]
34. A Prospective Comparison of
Anttinen M; Ettala O; Malaspina S; Jambor I; Sandell M; Kajander S; Rinta-Kiikka I; Schildt J; Saukko E; Rautio P; Timonen KL; Matikainen T; Noponen T; Saunavaara J; Löyttyniemi E; Taimen P; Kemppainen J; Dean PB; Blanco Sequeiros R; Aronen HJ; Seppänen M; Boström PJ
Eur Urol Oncol; 2021 Aug; 4(4):635-644. PubMed ID: 32675047
[TBL] [Abstract][Full Text] [Related]
35. Concordance between Response Assessment Using Prostate-Specific Membrane Antigen PET and Serum Prostate-Specific Antigen Levels after Systemic Treatment in Patients with Metastatic Castration Resistant Prostate Cancer: A Systematic Review and Meta-Analysis.
Han S; Woo S; Kim YI; Lee JL; Wibmer AG; Schoder H; Ryu JS; Vargas HA
Diagnostics (Basel); 2021 Apr; 11(4):. PubMed ID: 33917006
[TBL] [Abstract][Full Text] [Related]
36. New insights in the paradigm of upregulation of tumoral PSMA expression by androgen receptor blockade: Enzalutamide induces PSMA upregulation in castration-resistant prostate cancer even in patients having previously progressed on enzalutamide.
Rosar F; Dewes S; Ries M; Schaefer A; Khreish F; Maus S; Bohnenberger H; Linxweiler J; Bartholomä M; Ohlmann C; Ezziddin S
Eur J Nucl Med Mol Imaging; 2020 Mar; 47(3):687-694. PubMed ID: 31901103
[TBL] [Abstract][Full Text] [Related]
37. Consensus on diagnosis and management of non-metastatic castration resistant prostate cancer in Brazil: focus on patient, selection, treatment efficacy, side effects and physician's perception according to patient comorbidities.
Maluf F; Soares A; Avanço G; Hada AL; Cardoso APG; Carneiro A; Herchenhorn D; Jardim DLF; Schutz FA; Kater FR; Pereira FMT; Monteiro FSM; Morbeck IAP; Reolon JFN; da Trindade KM; Andrade LMQDS; Nogueira LM; Furoni R; Natel RA; Dos Reis RB; Fogace RN; Souza VC
Int Braz J Urol; 2021; 47(2):359-373. PubMed ID: 33284538
[TBL] [Abstract][Full Text] [Related]
38. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer.
Fizazi K; Smith MR; Tombal B
Clin Genitourin Cancer; 2018 Oct; 16(5):332-340. PubMed ID: 30197098
[TBL] [Abstract][Full Text] [Related]
39. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
Emmett L; Subramaniam S; Joshua AM; Crumbaker M; Martin A; Zhang AY; Rana N; Langford A; Mitchell J; Yip S; Francis R; Hofman MS; Sandhu S; Azad A; Gedye C; McJannett M; Stockler MR; Davis ID;
BJU Int; 2021 Nov; 128(5):642-651. PubMed ID: 34028967
[TBL] [Abstract][Full Text] [Related]
40. Rapid Modulation of PSMA Expression by Androgen Deprivation: Serial
Emmett L; Yin C; Crumbaker M; Hruby G; Kneebone A; Epstein R; Nguyen Q; Hickey A; Ihsheish N; O'Neill G; Horvath L; Chalasani V; Stricker P; Joshua AM
J Nucl Med; 2019 Jul; 60(7):950-954. PubMed ID: 30552200
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
